NRx Pharmaceuticals is a clinical stage pharmaceutical company that is developing, through its wholly owned operating subsidiary, NeuroRx, NRX-100 and NRX-101, the first oral therapeutic for the treatment of Bipolar Depression in patients with Acute Suicidal Ideation and Behavior (ASIB) and Sub-Acute Suicidal Ideation and Behavior (“SSIB”). NRX-100 and NRX-101 were developed based upon 30 years of basic science and clinical expertise contributed by Dr. Daniel Javitt, MD, PhD, related to the role of the brain’s N-methyl-D-aspartate (“NMDA”) receptor in regulating human thought processes in general and in regulating depression and suicidality. The NRX-100 and NRX-101 investigational therapy begins with a single dose of ketamine (NRX-100), a Food & Drug Administration (“FDA”) approved anesthetic, followed by approximately six weeks of daily oral NRX-101. NRX-101 is being developed as a rapid-onset and sustained treatment for bipolar depression with ASIB and SSIB. NRX-101 combines d-Cycloserine, a NMDA receptor modulator, and lurasidone, a 5-HT2a receptor antagonist.
Company profile
Ticker
NRXP
Exchange
Website
CEO
Richard S. Ackerman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Big Rock Partners Acquisition Corp.
SEC CIK
NRXP stock data
Latest filings (excl ownership)
8-K
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
19 Apr 24
424B5
Prospectus supplement for primary offering
19 Apr 24
424B5
Prospectus supplement for primary offering
18 Apr 24
8-K
Other Events
15 Apr 24
424B3
Prospectus supplement
15 Apr 24
424B3
Prospectus supplement
15 Apr 24
8-K
Four potential near-term milestones, including data from two clinical trials, an NDA filing and an upcoming share dividend
2 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
28 Mar 24
8-K
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
21 Mar 24
Transcripts
NRXP
Earnings call transcript
2023 Q4
1 Apr 24
NRXP
Earnings call transcript
2023 Q3
14 Nov 23
NRXP
Earnings call transcript
2023 Q2
14 Aug 23
NRXP
Earnings call transcript
2023 Q1
16 May 23
NRXP
Earnings call transcript
2022 Q4
30 Mar 23
NRXP
Earnings call transcript
2022 Q3
14 Nov 22
NRXP
Earnings call transcript
2022 Q2
15 Aug 22
NRXP
Earnings call transcript
2022 Q1
16 May 22
NRXP
Earnings call transcript
2021 Q4
31 Mar 22
NRXP
Earnings call transcript
2021 Q3
16 Nov 21
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 8.90 mm | 8.90 mm | 8.90 mm | 8.90 mm | 8.90 mm | 8.90 mm |
Cash burn (monthly) | 2.02 mm | 778.92 k | 1.94 mm | 2.78 mm | 1.52 mm | 2.23 mm |
Cash used (since last report) | 13.96 mm | 5.38 mm | 13.37 mm | 19.17 mm | 10.50 mm | 15.41 mm |
Cash remaining | -5.06 mm | 3.52 mm | -4.46 mm | -10.27 mm | -1.60 mm | -6.51 mm |
Runway (months of cash) | -2.5 | 4.5 | -2.3 | -3.7 | -1.1 | -2.9 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 35 |
Opened positions | 6 |
Closed positions | 3 |
Increased positions | 6 |
Reduced positions | 5 |
13F shares | Current |
---|---|
Total value | 4.80 bn |
Total shares | 11.14 mm |
Total puts | 4.50 k |
Total calls | 105.80 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Armistice Capital | 5.64 mm | $2.73 bn |
Vanguard | 1.48 mm | $714.69 mm |
Sabby Management | 699.73 k | $338.32 mm |
Big Rock Partners Sponsor | 655.57 k | $15.90 mm |
BRAC Lending | 590.44 k | $14.32 mm |
CVI | 483.57 k | $233.81 mm |
Geode Capital Management | 378.67 k | $183.09 mm |
BLK Blackrock | 290.71 k | $140.56 mm |
RY Royal Bank Of Canada | 171.23 k | $83.00 mm |
Bridgeway Capital Management | 160.70 k | $77.70 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
30 Aug 23 | Hurvitz Chaim | Common Stock, par value $0.001 per share | Buy | Acquire P | No | No | 0.2875 | 70,000 | 20.13 k | 570,000 |
30 Aug 23 | Aaron Gorovitz | Common Stock, par value $0.001 per share | Buy | Acquire P | Yes | No | 0.3199 | 35,000 | 11.20 k | 105,000 |
23 Aug 23 | Javitt Jonathan C | Common Stock | Buy | Acquire P | No | No | 0.33 | 100,000 | 33.00 k | 446,332 |
News
Nasdaq Down 0.5%; Lithium Americas Shares Slide
18 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
18 Apr 24
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
18 Apr 24
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
18 Apr 24
Press releases
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
18 Apr 24
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
18 Apr 24
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
17 Apr 24
New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intravenous and Subcutaneous Use: NRx Pharmaceuticals (Nasdaq: NRXP)
17 Apr 24
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
17 Apr 24